Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603896's PB Ratio is ranked better than 74.57% of 1227
companies
in the Biotechnology industry
Industry Median: 2.75
vs SHSE:603896: 1.27
During the past 12 months, Zhejiang Shouxiangu Pharmaceutical Co's average Book Value Per Share Growth Rate was -2.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 15.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Zhejiang Shouxiangu Pharmaceutical Co was 38.60% per year. The lowest was 5.70% per year. And the median was 15.50% per year.
Back to Basics: PB Ratio
Zhejiang Shouxiangu Pharmaceutical Co (SHSE:603896) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zhejiang Shouxiangu Pharmaceutical Co PB Ratio Related Terms
Zhejiang Shouxiangu Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Shouxiangu Pharmaceutical Co PB Ratio Chart
SHSE:603896 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Zhejiang Shouxiangu Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Shouxiangu Pharmaceutical Co PB Ratio vs Biotechnology Industry
Zhejiang Shouxiangu Pharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zhejiang Shouxiangu Pharmaceutical Co (SHSE:603896) has a PB Ratio of 1.27 as of Jul. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhejiang Shouxiangu Pharmaceutical Co and its competitors. This is 70% below median its historical median of 4.17. Over the past decade, Zhejiang Shouxiangu Pharmaceutical Co's PB Ratio has ranged from 1.13 to 13.41. According to the industry distribution chart, Zhejiang Shouxiangu Pharmaceutical Co ranks #312 out of 1227 companies in the Biotechnology industry, placing it in the top 25.4%.
Is Zhejiang Shouxiangu Pharmaceutical Co's PB Ratio too high?
Zhejiang Shouxiangu Pharmaceutical Co's current PB Ratio of 1.27 is 70% below median its 10-year median of 4.17. Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 13.41. The Biotechnology industry median PB Ratio is 2.75. Zhejiang Shouxiangu Pharmaceutical Co's value of 1.27 is 53.8% below this industry median. Based on the distribution chart, Zhejiang Shouxiangu Pharmaceutical Co ranks #312 out of 1227 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhejiang Shouxiangu Pharmaceutical Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Shouxiangu Pharmaceutical Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang Shouxiangu Pharmaceutical Co ranks #312 out of 1227 companies for PB Ratio. This puts Zhejiang Shouxiangu Pharmaceutical Co in the upper half of its industry. The industry median PB Ratio is 2.75. Zhejiang Shouxiangu Pharmaceutical Co's value of 1.27 is 53.8% below this benchmark. Historically, Zhejiang Shouxiangu Pharmaceutical Co's own PB Ratio has ranged from 1.13 to 13.41 over the past decade. While the company's 10-year median is 4.17 vs. the industry median of 2.75, Zhejiang Shouxiangu Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.75, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Shouxiangu Pharmaceutical Co's current PB Ratio of 1.27 is 53.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhejiang Shouxiangu Pharmaceutical Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Shouxiangu Pharmaceutical Co's current PB Ratio is 1.27, which is 70% below median its own 10-year median of 4.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Shouxiangu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Shouxiangu Pharmaceutical Co (SHSE:603896) is currently considered Possible Value Trap. The stock's GF Value™ is ¥22.84, compared to a current price of ¥14.63 — trading 35.9% below its estimated fair value. The current PB Ratio is 1.27, which is 70% below median its 10-year median of 4.17 and 53.8% below the Biotechnology industry median of 2.75. Zhejiang Shouxiangu Pharmaceutical Co's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zhejiang Shouxiangu Pharmaceutical Co (SHSE:603896), the current PB Ratio is 1.27 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Shouxiangu Pharmaceutical Co (SHSE:603896) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Shouxiangu Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥14.63 is trading 35.9% below its estimated GF Value™ of ¥22.84.
GuruFocus considers Zhejiang Shouxiangu Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for SHSE:603896:
PB Ratio: 1.27 (70% below median its 10-year median of 4.17)
GF Value™: ¥22.84 vs. price of ¥14.63 (35.9% below fair value)
Industry Position: 53.8% below the Biotechnology median (#312 of 1227)
No single metric tells the full story. See the SHSE:603896 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Shouxiangu Pharmaceutical Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603896 has been successfully added to your 
